本文選題：保婦康栓　切入點(diǎn)：抗HPV生物蛋白敷料　出處：《湖北中醫(yī)藥大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：目的探討保婦康栓聯(lián)合抗HPV生物蛋白敷料治療宮頸高危型人乳頭瘤病毒感染(主要為HPV16或18型感染)的有效性,試圖尋找一種有效的抗高危型HPV感染的方法,從而及時(shí)阻止疾病的進(jìn)一步發(fā)展,降低癌前病變及宮頸癌的發(fā)生率。方法選取武漢市第四醫(yī)院2016年1月至2016年9月門診收治的90例確診為宮頸高危型HPV感染的患者,隨機(jī)分成3組,每組30例,均在月經(jīng)干凈3天后開始用藥,于每晚睡前用溫水清洗外陰后將藥物置于陰道后穹隆,用藥和觀察期間若有性生活需使用避孕套。保婦康栓組:1次/d,2粒/次,16天1個(gè)療程,連用3個(gè)療程;抗HPV生物蛋白輔料組:1支/d,隔日1次,10次1個(gè)療程,連用3個(gè)療程;聯(lián)合用藥組:抗HPV生物蛋白敷料1支/d,保婦康栓2粒/d,兩藥交替使用,各用10天,20天為一療程,連用3個(gè)療程。在停藥一個(gè)月后分別復(fù)查每組患者的臨床癥狀(分泌物多、性交后出血)、宮頸糜爛程度、實(shí)驗(yàn)室檢查(HPV分型、血常規(guī)、尿常規(guī)、肝功能、腎功能);停藥三個(gè)月后再次對(duì)每組患者進(jìn)行HPV分型檢測(cè)。結(jié)果1、停藥一個(gè)月后保婦康栓聯(lián)合抗HPV生物蛋白敷料治療高危型HPV感染療效顯著,總有效率達(dá)76.7%,明顯高于其他兩組(保婦康栓組總有效率46.7%,抗HPV生物蛋白敷料組總有效率66.7%)。2、停藥一個(gè)月后保婦康栓聯(lián)合抗HPV生物蛋白敷料治療高危型HPV感染的臨床癥狀改善顯著,總有效率達(dá)70%,明顯高于其他兩組(保婦康栓組總有效率33%,抗HPV生物蛋白敷料組總有效率53%)。3、停藥一個(gè)月后保婦康栓聯(lián)合抗HPV生物蛋白敷料、保婦康栓組、抗HPV生物蛋白敷料組治療宮頸糜爛的有效率分別為16.7%、10%、6.67%,差異無統(tǒng)計(jì)學(xué)意義(P0.05)。4、安全性觀察:三組患者治療前后血常規(guī)、尿常規(guī)、肝功能、腎功能均無異常變化,未出現(xiàn)不良事件。5、停藥三個(gè)月后保婦康栓聯(lián)合抗HPV生物蛋白敷料治療高危型HPV感染療效顯著,總有效率達(dá)86.7%,明顯高于其他兩組(保婦康栓組總有效率66.7%,抗HPV生物蛋白敷料組總有效率73.3%)。結(jié)論保婦康栓聯(lián)合抗HPV生物蛋白敷料治療高危型HPV感染療效顯著,能明顯改善臨床癥狀,提高h(yuǎn)r-HPV轉(zhuǎn)陰率,療效優(yōu)于單用其中任何一種藥物,且臨床應(yīng)用安全可靠,無明顯毒副作用。
[Abstract]:Objective to explore the efficacy of Baofukang suppository combined with anti-#en0# bioprotein dressing in the treatment of high-risk human papillomavirus infection (mainly HPV16 or type 18 infection), and to find an effective method for the treatment of high-risk HPV infection. In order to prevent the further development of the disease and reduce the incidence of precancerous lesions and cervical cancer in time, 90 patients diagnosed as high-risk cervical HPV infection were selected from January 2016 to September 2016 in Wuhan 4th Hospital. They were randomly divided into 3 groups, 30 cases in each group, all of whom began taking drugs after 3 days of menstruation, and then washed the vulva with warm water before going to bed every night, then placed the drugs in the posterior vagina fornix. During the period of medication and observation, condoms should be used if there was sexual life. In the Baofukang suppository group, one treatment course was 1: 1 / d / L, and 3 courses of treatment were continuously used, while in the anti HPV bioprotein excipient group, 10 courses of treatment were given 10 times a day, and 3 courses of treatment were continued, and that of the anti HPV bioprotein excipients group was 10 times a day, 10 times a course of treatment every other day. The combined treatment group: 1 / d of anti HPV biological protein dressing, 2 / d of Baofukang suppository, 2 / d of Baofukang suppository, alternately used for 10 days and 20 days each as a course of treatment, 3 consecutive courses of treatment. After one month of withdrawal, the clinical symptoms (more secretions) of each group were re-examined respectively. Bleeding after sexual intercourse, degree of cervical erosion, laboratory examination of HPV typing, blood routine, urine routine, liver function, After three months of withdrawal, HPV typing was performed again in each group. Results 1. One month after withdrawal, Baofukang suppository combined with anti HPV bioprotein dressing was effective in the treatment of high risk HPV infection. The total effective rate was 76. 7, which was significantly higher than that of the other two groups (the total effective rate of Baofukang suppository group was 46. 7%, the total effective rate of anti-HPV bioprotein dressing group was 66. 7%. The clinical symptoms of Baofukang suppository combined with anti-HPV bioprotein dressing in the treatment of high-risk HPV infection were improved significantly after one month. The total effective rate was significantly higher than that of the other two groups (Baofukang suppository group, anti-#en0# bioprotein dressing group, total effective rate, 530.3. one month after the withdrawal, Baofukang suppository combined with anti-#en1# bioprotein dressing, Baofukang suppository combined with anti-#en1# bioprotein dressing, Baofukang suppository group, Baofukang suppository group, The effective rates of anti-#en0# bioprotein dressing group were 16.710 and 6.67, respectively. The difference was not statistically significant (P0.05. 4). Safety observation: before and after treatment, there were no abnormal changes in blood routine, urine routine, liver function and renal function in the three groups of patients, and there were no abnormal changes in blood routine examination, urine routine examination, liver function and renal function before and after treatment. There were no adverse events. 5. The efficacy of Baofukang suppository combined with anti HPV bioprotein dressing in the treatment of high risk HPV infection was significant three months after withdrawal. The total effective rate was 86.7, which was significantly higher than that of the other two groups (the total effective rate of Baofukang suppository group was 66.7, and the total effective rate of anti-#en0# bioprotein dressing group was 73.30.Conclusion the efficacy of Baofukang suppository combined with anti-#en1# bioprotein dressing in the treatment of high-risk HPV infection was significant. It can obviously improve the clinical symptoms and increase the negative rate of hr-HPV. The curative effect is better than that of any one of the drugs alone, and the clinical application is safe and reliable, and there is no obvious side effect.
【學(xué)位授予單位】：湖北中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R737.33

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 王清;陳永華;謝敏;李霞;吳春;;內(nèi)補(bǔ)丸聯(lián)合溫和灸治療帶下過多(腎陽虛型)臨床研究[J];亞太傳統(tǒng)醫(yī)藥;2016年02期

2 李玲;;李發(fā)枝教授運(yùn)用清肝利濕湯治療宮頸HPV感染經(jīng)驗(yàn)[J];中醫(yī)研究;2014年11期

3 劉永;黃慧榮;范湘玲;梅順利;;復(fù)方沙棘籽油栓治療高危型HPV感染效果觀察[J];現(xiàn)代中西醫(yī)結(jié)合雜志;2014年02期

4 楊雪萍;;重組人干擾素α-2a凝膠配合微波治療宮頸持續(xù)HPV感染性疾病的臨床療效觀察[J];中國婦幼保健;2013年11期

5 湯欣;韓鳳娟;李威;王龍;蔡冬燕;吳效科;;莪術(shù)醇對(duì)人卵巢癌SKOV3細(xì)胞株JAK2/STAT3信號(hào)通路影響的研究[J];中國婦產(chǎn)科臨床雜志;2013年01期

6 侯萌;李娜;朱廣霞;崔緒琴;安瑞芳;;婦科門診患者宮頸人乳頭瘤病毒的感染情況分析[J];西安交通大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2013年02期

7 黃偉蓮;何若英;黃瓊娟;;中醫(yī)治未病聯(lián)合健康管理在宮頸癌危險(xiǎn)因子HPV感染患者中的臨床應(yīng)用[J];齊齊哈爾醫(yī)學(xué)院學(xué)報(bào);2012年09期

8 趙廣榮;;重組人干擾素的研究進(jìn)展[J];中國生物制品學(xué)雜志;2010年12期

9 卞美璐;陳慶云;朱鵑;馬莉;郝敏;劉軍;陳穎;;保婦康栓治療宮頸持續(xù)人乳頭瘤病毒感染炎性疾病的臨床觀察[J];中國實(shí)用婦科與產(chǎn)科雜志;2010年05期

10 劉玉珍;于麗娟;;沙棘藥理作用綜述[J];中國科技信息;2009年16期

，

本文編號(hào)：1566804